Santa Barbara, May 21, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, CA, May 21, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNP) using “click chemistry”, for targeting cancer cells.
Click chemistry is a revolutionary approach to chemical synthesis that won the Nobel Prize in Chemistry 2022. It is characterized by high efficiency, high reliability, and simplicity in making precise molecular structures, such as LNPs, quickly and cost-effectively. In other words, you “click” together what you need and not anything else. The current approach to manufacturing LNPs uses imprecise melamine chemistry where unwanted materials end up in the final product, leading to toxicity and low efficiency.
The LNP is the vehicle that carries the functional cargoes of the Company’s Universal Cancer Vaccine (“UCV”) to precisely detect, mark and kill cancer cells. UCV uses multiple targeting signals to detect cancer cells with precision, as opposed to the conventional single signal targeting. By using click chemistry, the UCLA team has successfully created a customizable precision LNP architecture where various antibodies can be “clicked” onto the outside. These antibodies only bind to matching proteins (aka antigens) on the cancer cell surface like a lock-and-key mechanism. Once attached to the cell surface, the LNP would then enter the cancer cell and release additional UCV molecules that perform additional matching inside the cell to confirm that the cell is in fact a cancer cell. This multi-signal targeting is the very foundation of UCV’s high precision targeting of cancer cells.
CancerVax CEO, Byron Elton, said, “We believe that precision targeting of cancer cells is vital to better patient outcome and higher quality of care. Previous generations of cancer treatments such as chemotherapy, radiation, surgery and even other cancer vaccines are not that precise – as many people already know. Our UCV is a revolutionary concept. It is an outside the box approach that leverages state-of-the-art bioengineering and molecular technologies to develop a better way to treat cancer, by precisely detecting, marking, and killing cancer cells. The UCLA team continues to tell us that they are very excited about this ‘fresh-thinking’ approach and are working tirelessly to advance the development of our Universal Cancer Vaccine platform.”
About Us
CancerVax, Inc. is a pre-clinical biotechnology company developing breakthrough cancer drugs that will use the body’s immune system to fight cancer. Working with a team of world class cancer researchers and oncologists at UCLA, we intend to create a Universal Cancer Vaccine that will detect, mark, and destroy only the diseased cells with incredible precision. Like the COVID-19 vaccines that train the body to recognize and destroy the coronavirus, our cancer vaccine will leverage the body’s immune system to destroy cancer cells. Also working with UCLA, we have created our first cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. Based on the positive data, we plan to launch FDA IND enabling studies needed to apply for approval to proceed with human trials. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer. To learn more, please visit www.CancerVax.com
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.
Press Contact:
CancerVax, Inc.
Tel: (805) 356-1810
communications@CancerVax.com
